These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

152 related items for PubMed ID: 9239474

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Relation of free PSA/total PSA in serum for differentiating between patients with prostatic cancer and benign hyperplasia of the prostate: which cutoff should be used?
    Lein M, Stephan C, Jung K, Schnorr D, Loening S.
    Cancer Invest; 1998; 16(1):45-9. PubMed ID: 9474251
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic "gray zone" of total PSA 4 to 10 ng/mL.
    Kwiatkowski MK, Recker F, Piironen T, Pettersson K, Otto T, Wernli M, Tscholl R.
    Urology; 1998 Sep; 52(3):360-5. PubMed ID: 9730444
    [Abstract] [Full Text] [Related]

  • 6. [Prostate-specific antigen as a tumor marker of prostate carcinoma].
    Wymenga LF, Mensink HJ.
    Ned Tijdschr Geneeskd; 1999 Aug 21; 143(34):1733-8. PubMed ID: 10494319
    [Abstract] [Full Text] [Related]

  • 7. Free and complexed prostate specific antigen in the differentiation of benign prostatic hyperplasia and prostate cancer: studies in serum and plasma samples.
    España F, Royo M, Martínez M, Enguídanos MJ, Vera CD, Estellés A, Aznar J, Jiménez-Cruz JF, Heeb MJ.
    J Urol; 1998 Dec 21; 160(6 Pt 1):2081-8. PubMed ID: 9817329
    [Abstract] [Full Text] [Related]

  • 8. The combination of human glandular kallikrein and free prostate-specific antigen (PSA) enhances discrimination between prostate cancer and benign prostatic hyperplasia in patients with moderately increased total PSA.
    Magklara A, Scorilas A, Catalona WJ, Diamandis EP.
    Clin Chem; 1999 Nov 21; 45(11):1960-6. PubMed ID: 10545066
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. The role of prostate-specific antigen in the evaluation of benign prostatic hyperplasia.
    Tchetgen MB, Oesterling JE.
    Urol Clin North Am; 1995 May 21; 22(2):333-44. PubMed ID: 7539179
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Free to complexed PSA ratio in differentiating benign prostate hyperplasia from prostate cancer.
    Filella X, Alcover J, Corral JM, Molina R, Beardo P, Ballesta AM.
    Anticancer Res; 2001 May 21; 21(5):3717-20. PubMed ID: 11848550
    [Abstract] [Full Text] [Related]

  • 18. A multicenter clinical trial on the use of alpha1-antichymotrypsin-prostate-specific antigen in prostate cancer diagnosis.
    Lein M, Jung K, Hammerer P, Graefen M, Semjonow A, Stieber P, Ossendorf M, Luboldt HJ, Brux B, Stephan C, Schnorr D, Loening SA.
    Prostate; 2001 May 01; 47(2):77-84. PubMed ID: 11340629
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Molecular forms of prostate-specific antigen and human kallikrein 2 as promising tools for early diagnosis of prostate cancer.
    Stephan C, Jung K, Lein M, Sinha P, Schnorr D, Loening SA.
    Cancer Epidemiol Biomarkers Prev; 2000 Nov 01; 9(11):1133-47. PubMed ID: 11097220
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.